Reviva reports Q3 net loss of $4.0M; cash $13.2M; pre-NDA meeting with FDA on track

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Net loss of $4.0M ($0.06 per share) for Q3 2025, compared to $8.4M ($0.25) in Q3 2024.
Cash and cash equivalents totaled $13.2M as of September 30, 2025.
Pre-NDA meeting with FDA planned for Q4 2025; NDA submission for schizophrenia targeted for Q2 2026.
European patent granted covering use of brilaroxazine for treatment of pulmonary fibrosis.
Closed public equity offering with gross proceeds of $9.0M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.